Top 10 perkins.org.au Competitors

sahmri.org.au

Sign up to 'A Window on SAHMRI', the official SAHMRI Newsletter.

qeiimc.health.wa.gov.au

If you are experiencing a medical emergency call 000. Discover the Queen Elizabeth II Medical Centre (QEIIMC) - the largest medical centre in the southern hemisphere, dedicated to advanced patient care, cutting-edge research, and comprehensive education. Explore our services, parking information, and contact details for on-campus organisations.

scgh.health.wa.gov.au

sir charles gairdner hospital

fogartyfoundation.org.au

Supporting high-impact education & innovation initiatives in Western Australia, empowering students to achieve & create a positive social impact

proteomics.com.au

Jordana Sheahan, Iris Wang, Peter Galettis, Scott Bringans, David Watson, Kirsten Peters, Richard Lipscombe Diseases of the Esophagus, Volume 38, Issue Supplement_1, August 2025, doaf061.017, https://doi.org/10.1093/dote/doaf061.017 Published: 14 August 2025 Abstract Background: Esophageal adenocarcinoma (EAC) is often diagnosed at an advanced stage, leading to poor prognosis. The current standard of care involves endoscopy with biopsy in at-risk populations, which is invasive and expensive, yet increasing endoscopic surveillance programs have failed to significantly reduce EAC mortality. Significant to patient management, the pre-cancerous condition Barrett’s Esophagus with high grade dysplasia (BE-HGD) is often treated promptly upon detection similarly to early stage EAC. This study evaluates an alternative diagnostic strategy using the blood test Promarker®Eso, a previously validated serum glycoprotein biomarker panel for EAC, to detect EAC from stage I-IV and BE-HGD. Methods: The study analysed 350 people across two independent cohorts: cohort A compared 89 healthy controls with EAC samples of known stage (I: n = 16, II: n = 23, III: n = 16, IV: n = 3); cohort B compared 40 negative controls with unstaged EAC (n = 48) with n = 115 BE samples. The multivariate PromarkerEso test measures four glycoprotein biomarker concentrations (alpha-1-antitrypsin, alpha-1-antichymotrypsin, complement C9 and plasma kallikrein) using a lectin-based magnetic bead array pulldown method with targeted mass spectrometry, combined with simple clinical data (age, sex, BMI). Samples are categorised by predicted probability scores as low- (75%) risk of having EAC. Results: PromarkerEso exhibited robust discrimination performance for all stages of EAC with a minimum area under the curve (AUC) of 0.97. Concurrently, the test exhibited high sensitivity for EAC in all stages (I: 81%, II: 91%, III: 100%; IV: 100%) and also for BE-HGD (93%). Additionall

dmpi.duke.edu

We are pleased to announce the selection of two new DMPI Borden Scholar Awards for 2024. Made possible by a generous recurring gift to DMPI from Ernie and Louise Borden, these awards are given to outstanding postdoctoral trainees based on proposals reviewed by a senior faculty committee. Pictured are this year’s awardees, Dr. Andrew Cangelosi (left), and Dr. Adrian Epstein (right). Dr. Cangelosi is a fellow in the laboratory of Dr.

c-path.org

The newest Critical Path Institute® (C-Path) podcast features Ron Bartek, president and co-founder of the Friedreich’s Ataxia

springworkstx.com

We relentlessly pursue every possibility to create new cancer breakthroughs and power our approach with people who think hard, care hard, and act with urgency. %

corvuspharma.com

corvus pharmaceuticals is a clinical science-driven biopharmaceutical company focused on the development of cleverly-designed medicines with precise mechanisms of action to improve the lives of patients with the most difficult-to-treat cancers.

wchri.org

For 20 years, WCHRI has been filling critical gaps in women’s and children’s health research — powered by partnership and collaboration.